European Journal of Clinical Microbiology and Infectious Diseases

, Volume 13, Issue 11, pp 915–924

Mycobacterium avium complex: Advances in therapy

  • D. V. Havlir
Current Topic: Review

DOI: 10.1007/BF02111492

Cite this article as:
Havlir, D.V. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13: 915. doi:10.1007/BF02111492

Abstract

DisseminatedMycobacterium avium complex (MAC) is one of the most common opportunistic infections in AIDS patients and is increasingly recognized as a significant pathogen in chronic pulmonary disease in nonimmunocompromised patients. Important progress in therapy has occurred over the last several years. In AIDS patients, multidrug therapy has been shown to be beneficial in terms of reducing circulating bacteremia and improving clinical symptoms. Clarithromycin and azithromycin, two broad-spectrum antimicrobials with minimal activity againstMycobacterium tuberculosis, have emerged as potent, well tolerated agents pivotal to treatment regimens. In AIDS patients, rifabutin prophylaxis reduced the frequency of MAC bacteremia by 50 % in two placebo controlled trials. Despite these advances, there remains a need for determining the optimal combination regimens for therapy, and more effective drugs for prophylaxis which are beneficial both in terms of survival and functional capacity of patients.

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1994

Authors and Affiliations

  • D. V. Havlir
    • 1
  1. 1.Department of Internal Medicine, Division of Infectious DiseaseUniversity of CaliforniaSan DiegoUSA